

**Breath volatile metabolome reveals the impact of dietary fibres on the gut
microbiota: proof of concept in healthy volunteers**

Audrey M. Neyrinck, Julie Rodriguez, Zhengxiao Zhang, Julie-Anne Nazare, Laure B. Bindels,
Patrice D. Cani, Véronique Maquet, Martine Lavoie, Stephan C. Bischoff, Jens Walter and Nathalie
M. Delzenne

Supplementary Materials

Table S1. Baseline characteristics of participants ¹

Women/men N (%)	8/7 (53/47)
Age (years old)	21 ± 2
Body weight (kg)	67.3 ± 10.5
BMI (kg/m ²)	22.3 ± 2.0
SBP, mm Hg	123.1 ± 11.3
DBP, mm Hg	76.9 ± 6.1

¹Values are means ± SD. BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure




Figure S1. Untargeted analysis of breath from 15 healthy subjects prior (day 0) and after (day 21) chitin-glucan intake during 3 weeks. Principal component analysis (PCA) score plots obtained from the MS-fragment spectra (H_3O^+ , NO^+ and O_2^+ ionizations using SIFT-MS) at different times after the breakfast rich in dietary fibre.




Figure S2. Targeted BVM concentrations presented in absolute values (ppm) exhaled in the breath of healthy subjects (n=15) prior (day 0) and after (day 21) chitin-glucan intake. Data are medians \pm interquartile ranges (mixed model: §significant effect of treatment, #significant interaction between treatment and time, *Šídák post test: p<0.05).




Figure S3. Targeted BVM concentrations (changes from baseline) exhaled in breath of healthy subjects ($n=15$) in response to a standardized breakfast intake prior (day 0) and after (day 21) chitin-glucan intake (and not significantly affected by the chitin-glucan intake during 3 weeks). Data are medians \pm interquartile ranges ($p>0.05$; matched-pairs Wilcoxon signed-rank test on net area under the curve).

Table S2. Power calculation and effect size on targeted BVM significantly affected by the chitin-glucan treatment¹

	D0	D21	D21-D0	Power	Cohen's d
Butyric acid					
Mean	0,078	0,041	-0,036	62%	0,63
SD	0,042	0,032	0,057		
Butanol					
Mean	0,421	0,256	-0,165	90%	0,91
SD	0,128	0,119	0,182		
Caproic acid					
Mean	0,016	-0,004	-0,020	85%	0,83
SD	0,010	0,019	0,024		
Ethanol					
Mean	2,059	0,390	-1,669	90%	0,89
SD	2,134	1,721	1,864		
Methane					
Mean	163,700	96,260	-67,420	77%	0,75
SD	77,950	60,550	89,820		
Pentane					
Mean	2,451	0,969	-1,482	100%	2,07
SD	0,459	0,428	0,715		
Phenol					
Mean	2,151	0,806	-1,345	100%	3,20
SD	0,361	0,319	0,421		
Triethylamine					
Mean	0,009	0,004	-0,005	62%	0,66
SD	0,007	0,005	0,008		
3-hydroxubutanone					
Mean	0,048	0,030	-0,018	41%	0,48
SD	0,028	0,021	0,037		
2,3 butanedione					
Mean	0,682	0,007	-0,675	100%	3,82
SD	0,146	0,182	0,177		

¹Power computation was carried out on net AUC of BVM using the PASS 14.0.7 software with a significance level of 0,05 (Wilcoxon test) taking into account the difference (change after 21 days from day 0), the standard deviation (SD) and the sample size (n=15). Effect size was calculated with Cohen's d i.e. by dividing the mean difference by the SD of the difference (Cohen, 1998. *Statistical Power Analysis for the Behavioral Sciences*. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates).




Figure S4. Net area under the curves of targeted BVM concentrations exhaled in breath after the breakfast intake (a) and after the lunch intake (b) of healthy subjects (n=15) prior (day 0) and after (day 21) chitin-glucan. Data are medians \pm interquartile ranges (* $p < 0.05$; matched-pairs Wilcoxon signed-rank test on net area under the curve).

Table S3. Baseline score of gastrointestinal symptoms of the participants at fasting state¹

	Day 0		Day 21	
Nausea	0.3 ± 1.0	(0[0-0])	0.0 ± 0.0	(0[0-0])
Flatulence	2.7 ± 5.2	(0[0-3])	2.5 ± 5.4	(0[0-1])
Bloating	2.6 ± 4.9	(0[0-6])	4.1 ± 6.6	(0[0-9])
Cramp	1.5 ± 4.2	(0[0-0])	0.0 ± 0.0	(0[0-0])
Rumbling	6.3 ± 13.4	(0[0-14])	2.9 ± 7.9	(0[0-0])
Reflux	0.2 ± 0.8	(0[0-0])	0.1 ± 0.5	(0[0-0])
Discomfort	2.4 ± 4.7	(0[0-2])	2.1 ± 3.7	(0[0-4])
Burp	0.6 ± 1.8	(0[0-0])	0.1 ± 0.5	(0[0-0])

¹Values are means ± SD (medians [interquartile ranges]) (n=15, p > 0.05, matched-pairs Wilcoxon signed-rank test).



a**b**

Figure S5. Gastrointestinal tolerance of healthy subjects ($n=15$) about 8 symptoms assessed by visual analog scale (changes from baseline) in response to a standardized breakfast intake prior (day 0) and after (day 21) chitin-glucan intake during 3 weeks. Data are medians \pm interquartile ranges (a). Data are means \pm SD (b); $p > 0.05$; matched-pairs Wilcoxon signed-rank test on net AUC.